Estudios de práctica clínica real en esclerosis múltiple

Lucienne Costa-Frossard

doi:10.7399/fh.11663

Estudios de práctica clínica real en esclerosis múltiple

Lucienne Costa-Frossard

Resumen

Palabras clave

Texto completo:

PDF (English) PDF

Referencias

Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, 3rd edition. Mult Scler. 2020;26(14):1816-21. DOI: 10.1177/1352458520970841

Faissner S, Plemel JR, Gold R, Yong VW. Progressive multiple sclerosis: from pathophysiology to therapeutic strategies. Nat Rev Drug Discov. 2019;18(12):905-22. DOI: 10.1038/s41573-019- 0035-2

Reich DS, Lucchinetti CF, Calabresi PA. Multiple Sclerosis. N Engl J Med. 2018;378(2):169-80. DOI: 10.1056/NEJMra1401483

Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, et al. Placebocontrolled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367:1098-107.

Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, et al. Placebocontrolled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367:1087-97.

Gold R, Giovannoni G, Phillips JT, Bar-Or A, Fox RJ, Chen C, et al. Safety and efficacy in Patients Treated With Dimethyl Fumarate and Followed For 13 Years: final Results of ENDORSE. Conferencia: 8th Joint ACTRIMS-ECTRIMS Meeting (MSVirtual). 2020.

European Medicines Agency. Ficha técnica Tecfidera® Dimetil fumarato: Biogen Netherlands B.V. 2018 [accessed 02/01/2021]. Available at: https://www.ema.europa.eu/en/documents/product- information/tecfidera-epar-product-information_es.pdf

Cohen JA, Trojano M, Mowry EM, Uitdehaag BM, Reingold SC, Marrie RA. Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment. Mult Scler. 2020;26:23-37.

Peeters LM, Parciak T, Kalra D, Moreau Y, Kasilingam E, van Galen P, et al. Multiple sclerosis data alliance — a global multi-stakeholder collaboration to scale-up real world data research. Mult Scler Relat Disord. 2020;47:102634.

Mirabella M, Prosperini L, Lucchini M, Bofa L, Borriello G, Buscarinu MC, et al. Safety and efficacy of dimethyl fumarate in multiple sclerosis: an Italian, multicenter, real-world study. CNS Drugs. 2018;32(10):963-70. DOI: 10.1007/s4026 3-018-0543-3

Mallucci G, Annovazzi P, Miante S, Torri-Clerici V, Matta M, La Gioia S, et al. Twoyear real-life efficacy, tolerability and safety of dimethyl fumarate in an Italian multicentre study. J Neurol. 2018;265(8):1850-9. DOI: 10.1007/s00415-018-8916-6

Sabin J, Urtiaga S, Pilo B, Thuissard I, Galan V, de la Maza SS, et al. Tolerability and safety of dimethyl fumarate in relapsing multiple sclerosis: a prospective observational multicenter study in a real-life Spanish population. J Neurol. 2020;267(8):2362-71. DOI: 10.1007/s00415-020-09848-7

Berger T, Brochet B, Brambilla L, Giacomini PS, Montalbán X, Vasco Salgado A, et al. Effectiveness of delayed-release dimethyl fumarate on patient-reported outcomes and clinical measures in patients with relapsing-remitting multiple sclerosis in a real world clinical setting: PROTEC. Mult Scler J Exp Transl Clin. 2019;5(4):2055217319887191. DOI: 10.1177/20552 17319887191

Boullosa-Lale S, González-Freire L, Martínez-Martínez L, Crespo- Diz C. Seguridad y persistencia del dimetilfumarato como tratamiento para la esclerosis múltiple remitente-recurrente. Farm Hosp. 2021;45(2):XX-XX.

Sainz de la Maza S, Medina S, Villarrubia N, Costa-Frossard L, Monreal E, Tejeda-Velarde A, et al. Factors associated with dimethyl fumarate-induced lymphopenia. J Neurol Sci. 2019;398:4-8. DOI: 10.1016/j.jns.2019.01.007

DOI: http://dx.doi.org/10.7399%2Ffh.11663